Primary Site >> Biliary tract Cancer

Gene >> MAP2K7

Journal: Hepatology. 1997 Aug;26(2):288-94.
Title: Hepatocytic phenotypes induced in sarcomatous cholangiocarcinoma cells treated with 5-azacytidine.
Author: Enjoji, M|Nakashima, M|Honda, M|Sakai, H|Nawata, H
PMID: 9252136
Journal: Gut. 2003 May;52(5):706-12.
Title: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.
Author: Tannapfel, A|Sommerer, F|Benicke, M|Katalinic, A|Uhlmann, D|Witzigmann, H|Hauss, J|Wittekind, C
PMID: 12692057
Journal: Hepatology. 2003 May;37(5):1122-9.
Title: Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma.
Author: Tanaka, Shinji|Sugimachi, Keishi|Kameyama, Toshifumi|Maehara, Shin-Ichiro|Shirabe, Ken|Shimada, Mitsuo|Wands, Jack R|Maehara, Yoshihiko
PMID: 12717393
Journal: J Exp Clin Cancer Res. 2004 Dec;23(4):599-606.
Title: A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice.
Author: Horiuchi, H|Kawamata, H|Furihata, T|Omotehara, F|Hori, H|Shinagawa, Y|Ohkura, Y|Tachibana, M|Yamazaki, T|Ajiki, T|Kuroda, Y|Fujimori, T
PMID: 15743030
Journal: J Surg Res. 2006 Nov;136(1):78-84. Epub 2006 Sep 1.
Title: Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met.
Author: Leelawat, Kawin|Leelawat, Surang|Tepaksorn, Panada|Rattanasinganchan, Panthip|Leungchaweng, Anicha|Tohtong, Rutaiwan|Sobhon, Prasert
PMID: 16950403
Journal: J Cancer Res Clin Oncol. 2007 Apr;133(4):271-8. Epub 2006 Nov 25.
Title: Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells.
Author: Jinawath, Artit|Akiyama, Yoshimitsu|Sripa, Banchob|Yuasa, Yasuhito
PMID: 17294242
Journal: Oncol Rep. 2008 Oct;20(4):863-72.
Title: The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
Author: Matsumoto, Kazuya|Nagahara, Takakazu|Okano, Jun-Ichi|Murawaki, Yoshikazu
PMID: 18813828
Journal: Ann Oncol. 2010 Oct;21 Suppl 7:vii345-8.
Title: Advances in the treatment of metastatic or unresectable biliary tract cancer.
Author: Valle, J W
PMID: 20943640
Journal: Hepatogastroenterology. 2010 May-Jun;57(99-100):426-9.
Title: Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Author: Qun, Wang|Tao, Yin
PMID: 20698202
Journal: Curr Drug Targets. 2010 Jul;11(7):834-50.
Title: Molecular targeted therapy of biliary tract cancer--results of the first clinical studies.
Author: Wiedmann, Marcus W|Mossner, Joachim
PMID: 20388063
Journal: Biochem Biophys Res Commun. 2011 Feb 18;405(3):333-7.
Title: Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2.
Author: Yoon, Hyunho|Min, Jeong-Ki|Lee, Jung Whoi|Kim, Dae-Ghon|Hong, Hyo Jeong
PMID: 21130731
Journal: J Gastroenterol. 2011 Jun;46(6):779-89.
Title: Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Author: Sugiyama, Hiroaki|Onuki, Kenichiro|Ishige, Kazunori|Baba, Nobue|Ueda, Tetsuya|Matsuda, Sachiko|Takeuchi, Kaoru|Onodera, Masafumi|Nakanuma, Yasuni|Yamato, Masayuki|Yamamoto, Masakazu|Hyodo, Ichinosuke|Shoda, Junichi
PMID: 21331764
Journal: Br J Cancer. 2012 May 8;106(10):1583-6.
Title: Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.
Author: Prado, C M M|Bekaii-Saab, T|Doyle, L A|Shrestha, S|Ghosh, S|Baracos, V E|Sawyer, M B
PMID: 22510747
Journal: Clin Cancer Res. 2013 Jan 1;19(1):118-27.
Title: Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer.
Author: Xu, Junyao|Knox, Jennifer J|Ibrahimov, Emin|Chen, Eric|Serra, Stefano|Tsao, Ming|Cao, Pinjiang|Vines, Douglass|Green, David E|Metran-Nascente, Cristiane|McNamara, Mairead G|Hedley, David W
PMID: 23091117
Journal: Int J Oncol. 2013 Feb;42(2):690-8.
Title: Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma.
Author: Yang, Wei|Wang, Xiaoyuan|Zheng, Wei|Li, Kedong|Liu, Haofeng|Sun, Yueming
PMID: 23254774
Journal: Hepatology. 2013 Jun;57(6):2248-60.
Title: Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis.
Author: Cui, Xiang-Dan|Lee, Mi-Jin|Kim, Jong-Hyun|Hao, Pei-Pei|Liu, Lan|Yu, Goung-Ran|Kim, Dae-Ghon
PMID: 23315987
Journal: Oncotarget. 2013 Jan;4(1):156-65.
Title: Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
Author: Subbiah, Ishwaria M|Subbiah, Vivek|Tsimberidou, Apostolia M|Naing, Aung|Kaseb, Ahmed O|Javle, Milind|Fu, Siqing|Hong, David S|Piha-Paul, Sarina|Wheler, Jennifer J|Hess, Kenneth R|Janku, Filip|Falchook, Gerald S|Wolff, Robert A|Kurzrock, Razelle
PMID: 23391555
Journal: Am Soc Clin Oncol Educ Book. 2014:e165-70.
Title: A review of recent data in the treatment of gallbladder cancer: what we know, what we do, and what should be done.
Author: Muller, Bettina G|De Aretxabala, Xabier|Gonzalez Domingo, Manuel
PMID: 24857099
Journal: Ecancermedicalscience. 2014 Nov 6;8:479.
Title: Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.
Author: Loaiza-Bonilla, Arturo|Clayton, Erica|Furth, Emma|O'Hara, Mark|Morrissette, Jennifer
PMID: 25435907
Journal: Invest New Drugs. 2014 Dec;32(6):1144-54.
Title: Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
Author: Ewald, Florian|Norz, Dominik|Grottke, Astrid|Hofmann, Bianca T|Nashan, Bjorn|Jucker, Manfred
PMID: 25152244
Journal: Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):345-53.
Title: Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
Author: Schweitzer, N|Vogel, A
PMID: 25966433
Journal: J Gastroenterol. 2016 Jul;51(7):711-21.
Title: A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks.
Author: Mohri, Dai|Ijichi, Hideaki|Miyabayashi, Koji|Takahashi, Ryota|Kudo, Yotaro|Sasaki, Takashi|Asaoka, Yoshinari|Tanaka, Yasuo|Ikenoue, Tsuneo|Tateishi, Keisuke|Tada, Minoru|Isayama, Hiroyuki|Koike, Kazuhiko
PMID: 26614007
Journal: Oncotarget. 2016 Feb 2;7(5):5306-12.
Title: Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.
Author: Ahn, Daniel H|Ozer, Hatice Gulcin|Hancioglu, Baris|Lesinski, Gregory B|Timmers, Cynthia|Bekaii-Saab, Tanios
PMID: 26683364
Journal: J Exp Clin Cancer Res. 2016 Apr 16;35:68.
Title: Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer.
Author: Cao, Yang|Liang, Haibin|Zhang, Fei|Luan, Zhou|Zhao, Shuai|Wang, Xu-An|Liu, Shibo|Bao, Runfa|Shu, Yijun|Ma, Qiang|Zhu, Jian|Liu, Yingbin
PMID: 27084680
Journal: J Gastrointest Oncol. 2016 Dec;7(6):E98-E102.
Title: Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.
Author: Lavingia, Viraj|Fakih, Marwan
PMID: 28078132
Journal: Mol Cancer Ther. 2017 Feb;16(2):344-356.
Title: Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.
Author: Talbert, Erin E|Yang, Jennifer|Mace, Thomas A|Farren, Matthew R|Farris, Alton B|Young, Gregory S|Elnaggar, Omar|Che, Zheng|Timmers, Cynthia D|Rajasekera, Priyani|Maskarinec, Jennifer M|Bloomston, Mark|Bekaii-Saab, Tanios|Guttridge, Denis C|Lesinski, Grego
PMID: 27811010
Journal: Int J Mol Sci. 2017 Feb 15;18(2). pii: ijms18020418.
Title: Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
Author: Simone, Valeria|Brunetti, Oronzo|Lupo, Luigi|Testini, Mario|Maiorano, Eugenio|Simone, Michele|Longo, Vito|Rolfo, Christian|Peeters, Marc|Scarpa, Aldo|Azzariti, Amalia|Russo, Antonio|Ribatti, Domenico|Silvestris, Nicola
PMID: 28212293
Journal: Expert Opin Ther Targets. 2017 May;21(5):485-498.
Title: Signaling pathways as therapeutic targets in biliary tract cancer.
Author: Yang, Jennifer|Farren, Matthew R|Ahn, Daniel|Bekaii-Saab, Tanios|Lesinski, Gregory B
PMID: 28282502
Journal: Oncotarget. 2017 May 30;8(22):36319-36330.
Title: Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.
Author: Li, Mengdan|Chen, Lihong|Qu, Yiping|Sui, Fang|Yang, Qi|Ji, Meiju|Shi, Bingyin|Chen, Mingwei|Hou, Peng
PMID: 28422736
Journal: J Gastrointest Oncol. 2017 Apr;8(2):E32-E38.
Title: Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.
Author: Kocsis, Judit|Arokszallasi, Anita|Andras, Csilla|Balogh, Ingrid|Beres, Edit|Deri, Julia|Petak, Istvan|Janvary, Levente|Horvath, Zsolt
PMID: 28480077
Journal: Cancer Lett. 2017 Dec 28;411:162-170.
Title: Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
Author: Jin, Ling|Jin, Mei-Hua|Nam, Ah-Rong|Park, Ji-Eun|Bang, Ju-Hee|Oh, Do-Youn|Bang, Yung-Jue
PMID: 29024814
Journal: Cell Death Dis. 2018 Jan 18;9(2):31.
Title: Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model.
Author: Dong, Mingjie|Liu, Xianqiong|Evert, Katja|Utpatel, Kirsten|Peters, Michele|Zhang, Shanshan|Xu, Zhong|Che, Li|Cigliano, Antonio|Ribback, Silvia|Dombrowski, Frank|Cossu, Antonio|Gordan, John|Calvisi, Diego F|Evert, Matthias|Liu, Yan|Chen, Xin
PMID: 29348467
Journal: Cell Death Dis. 2018 Feb 7;9(2):179.
Title: Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of beta-Catenin.
Author: Zheng, Yan|Zhou, Chuang|Yu, Xin-Xin|Wu, Chao|Jia, Hu-Liang|Gao, Xiao-Mei|Yang, Ji-Meng|Wang, Chao-Qun|Luo, Qin|Zhu, Ying|Zhang, Yu|Wei, Jin-Wang|Sheng, Yuan-Yuan|Dong, Qiong-Zhu|Qin, Lun-Xiu
PMID: 29415992
Journal: Cancer Med. 2018 Mar;7(3):796-808.
Title: Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling.
Author: Peng, Rui|Zhang, Peng-Fei|Zhang, Chi|Huang, Xiao-Yong|Ding, Yan-Bing|Deng, Bin|Bai, Dou-Sheng|Xu, Ya-Ping
PMID: 29446253
Journal: Int J Mol Sci. 2018 Oct 12;19(10). pii: ijms19103141.
Title: MET Activation by a Macrocyclic Peptide Agonist that Couples to Biological Responses Differently from HGF in a Context-Dependent Manner.
Author: Miao, Wenyu|Sakai, Katsuya|Imamura, Ryu|Ito, Kenichiro|Suga, Hiroaki|Sakuma, Tetsushi|Yamamoto, Takashi|Matsumoto, Kunio
PMID: 30322054